2,3-dinitrobenzylalcohol | 858136-29-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,3-dinitrobenzylalcohol
• 英文别名: (2,3-dinitrophenyl)methanol
• CAS: 858136-29-5
• 化学式: C₇H₆N₂O₅
• 分子量: 198.135
• InChiKey: RCCCKRLZQBQNPW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  112
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2,3-dinitrobenzylalcohol 在 氢溴酸 作用下， 以 水 为溶剂， 反应 6.0h， 生成 2,3-dinitrobenzyl bromide
  参考文献：
  名称：

  [EN] THIAZOLE DERIVATIVES HAVING VAP-1 INHIBITORY ACTIVITY
  [FR] DERIVES DE THIAZOLE PRESENTANT UNE ACTIVITE D'INHIBITION DE LA VAP-1

  摘要：

  公开号：

  WO2006011631A3
• 作为产物：
  描述：

  2,3-二硝基苯甲酸 在 sodium tetrahydroborate 、 三氟化硼乙醚 、 盐酸 、 水 作用下， 以 四氢呋喃 为溶剂， 反应 2.45h， 生成 2,3-dinitrobenzylalcohol
  参考文献：
  名称：

  [EN] THIAZOLE DERIVATIVES HAVING VAP-1 INHIBITORY ACTIVITY
  [FR] DERIVES DE THIAZOLE PRESENTANT UNE ACTIVITE D'INHIBITION DE LA VAP-1

  摘要：

  公开号：

  WO2006011631A3

文献信息

• Novel compounds and compositions for treating diseases asociated with protease activity
  申请人：——

  公开号：US20010053779A1

  公开（公告）日：2001-12-20

  Novel compounds, compositions and methods effective for the prevention and treatment of mast-cell mediated inflammatory disorders are described. The compounds, compositions and methods are effective for the prevention and treatment of inflammatory diseases associated with the respiratory tract, such as asthma and allergic rhinitis, as well as other types of immunomediated inflammatory disorders, such as rheumatoid arthritis, conjunctivitis and inflammatory bowel disease, various dermatological conditions, as well as certain viral conditions. The compounds comprise potent and selective inhibitors of the mast cell protease tryptase. The compositions for treating these conditions include oral, inhalant, topical and parenteral preparations as well as devices comprising such preparations.

  描述了用于预防和治疗由肥大细胞介导的炎症性疾病的新化合物、组合物和方法。这些化合物、组合物和方法对预防和治疗与呼吸道相关的炎症性疾病（如哮喘和过敏性鼻炎）以及其他类型的免疫介导性炎症性疾病（如类风湿关节炎、结膜炎和炎症性肠病、各种皮肤病症以及某些病毒性疾病）有效。这些化合物包括对肥大细胞蛋白酶组胺酶的有效和选择性抑制剂。用于治疗这些疾病的组合物包括口服、吸入、局部和静脉制剂，以及包含这些制剂的装置。
• Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders
  申请人：Axys Pharmaceuticals, Inc.

  公开号：US20030212120A1

  公开（公告）日：2003-11-13

  Novel compounds, compositions and methods effective for the prevention and treatment of mast-cell mediated inflammatory disorders are described. The compounds, compositions and methods are effective for the prevention and treatment of inflammatory diseases associated with the respiratory tract, such as asthma and allergic rhinitis, as well as other types of immunomediated inflammatory disorders, such as rheumatoid arthritis, conjunctivitis and inflammatory bowel disease, various dermatological conditions, as well as certain viral conditions. The compounds comprise potent and selective inhibitors of the mast cell protease tryptase. The compositions for treating these conditions include oral, inhalant, topical and parenteral preparations as well as devices comprising such preparations.

  本发明描述了一种新型化合物、组合物和方法，用于预防和治疗由肥大细胞介导的炎症性疾病。这些化合物、组合物和方法对预防和治疗呼吸道相关的炎症性疾病，如哮喘和过敏性鼻炎，以及其他类型的免疫介导的炎症性疾病，如类风湿性关节炎、结膜炎和炎症性肠病、各种皮肤病和某些病毒性疾病均有效。这些化合物包括强效和选择性的肥大细胞蛋白酶酶抑制剂。治疗这些疾病的组合物包括口服、吸入、局部和静脉制剂，以及包含这些制剂的装置。
• Diamine, acid dianhydride, polymide composition having reactive group obtained therefrom, and processes for producing these
  申请人：——

  公开号：US20040158030A1

  公开（公告）日：2004-08-12

  The present invention relates to a novel diamine, a novel acid dianhydride, and a novel composition containing a polyimide produced from such diamine and acid dianhydride. Specifically, the present invention relates to an acid dianhydride that has a photosensitive group bonded through the mediation of an alkylene group or a fluoroalkylene group, a diamine that has a reactive group bonded through the mediation of an alkylene group or a fluoroalkylene group, and a polyimide composition that contains a novel polyimide having at least one of such acid dianhydride residue and diamine residue in a molecule thereof. Particularly, an object of the present invention is to provide a novel polyimide that has both photoreactivity and thermoreactivity specific to the reactive group and whose reactive group is selected from the group consisting of: organic groups derived from cinnamic acid, chalcone, furylacryloyl, benzalacetophenone, stilbene, coumarin, and pyrone; allyl; propargyl; ethinyl; CH 2 ═CH—; CH 2 ═C(CH 3 )—; and skeletons derived therefrom, and it to provide a novel diamine and a novel acid dianhydride that may be contained in the polyimide composition.

  本发明涉及一种新的二胺、一种新的酸二酐和一种含有由此类二胺和酸二酐制备的聚酰亚胺的新组合物。具体地，本发明涉及一种通过烷基或氟烷基介导的光敏基团键合的酸二酐，一种通过烷基或氟烷基介导的反应性基团键合的二胺，以及一种聚酰亚胺组合物，其分子中含有至少一个这样的酸二酐残基和二胺残基。特别地，本发明的目的是提供一种具有光反应性和热反应性的新型聚酰亚胺，其反应性基团来自以下群组：来自肉桂酸、查尔酮、呋喃丙烯酰、苯甲酰乙酮、亚苯基烯、香豆素和吡喃的有机基团；烯丙基；丙炔基；乙炔基；CH2═CH—；CH2═C(CH3)—；以及派生自这些基团的骨架，并提供可包含在聚酰亚胺组合物中的新型二胺和新型酸二酐。
• Method of producing liquid crystal aligning layer, liquid crystal aligning layer produced using the same, and liquid crystal display including liquid crystal aligning layer
  申请人：Kim Kyung-Jun

  公开号：US20070128378A1

  公开（公告）日：2007-06-07

  Disclosed is a method of producing a liquid crystal aligning layer, a liquid crystal aligning layer produced using the same, and a liquid crystal display including the liquid crystal aligning layer. In the liquid crystal aligning layer that is produced using the method, ultraviolet rays are radiated on movable chains of a polyamic acid polymer while the polyamic acid polymer is not imidized to perform alignment, and heat treatment is then performed to conduct imidization. Thus, thermal stability is excellent, residual images are not formed, and alignment of liquid crystals is excellent.

  本发明公开了一种制备液晶定向层的方法，使用该方法制备的液晶定向层以及包括该液晶定向层的液晶显示器。在使用该方法制备的液晶定向层中，当聚酰亚胺酸聚合物未进行亚酰亚胺化时，对聚酰亚胺酸聚合物的可移动链进行紫外线照射以进行定向，然后进行热处理以进行亚酰亚胺化。因此，热稳定性优异，不会形成残留图像，液晶的定向效果也很好。
• Thiazole Derivatives Having Vap-1 Inhibitory Activity
  申请人：Inoue Takayuki

  公开号：US20070254931A1

  公开（公告）日：2007-11-01

  A compound of the formula (I), (II), (III) or (IV): wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, a method for preventing or treating a VAP-1 associated disease, especially macular edema, which method includes administering an effective amount of the compound or a pharmaceutically acceptable salt thereof to a subject, and the like.

  公式（I），（II），（III）或（IV）的化合物：其中每个符号如规范中所定义，或其药学上可接受的盐，可用作血管黏附蛋白-1（VAP-1）抑制剂，制药组合物，预防或治疗VAP-1相关疾病，特别是黄斑水肿的方法，该方法包括向受试者投予化合物或其药学上可接受的盐的有效量等。